setogepram   Click here for help

GtoPdb Ligand ID: 10043

Synonyms: 3-pentylbenzeneacetic acid | fezagepras | PBI-4050 | PBI4050
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Setogepram (PBI-4050) is an orally active, synthetic analogue of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, respectively [1]. it is a potentially novel first-in-class compound with significant antifibrotic and antiinflammatory activities that was being developed by Liminal BioSciences (formerly Prometic Life Sciences).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 37.3
Molecular weight 206.13
XLogP 4.06
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCCCc1cccc(c1)CC(=O)O
Isomeric SMILES CCCCCc1cccc(c1)CC(=O)O
InChI InChI=1S/C13H18O2/c1-2-3-4-6-11-7-5-8-12(9-11)10-13(14)15/h5,7-9H,2-4,6,10H2,1H3,(H,14,15)
InChI Key PEGQOIGYZLJMIB-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
PBI-4050 reached Phase 2 clinical evaluation in a variety of inflammatory and fibrotic conditions. Click here to link to the complete list of PBI-4050 trials registered with ClinicalTrials.gov. Liminal BioSciences, who were developing the compound, decided not to progress it for IPF or hypertriglyceridemia following unsatisfactory interim pharmacokinetic results from their multiple-ascending dose study.